GSK announces positive outcomes from Phase I BEHOLD-1 trial of Mo-Rez
GSK has shared encouraging data from its Phase I BEHOLD-1 clinical trial of mocertatug rezetecan (Mo-Rez), an antibody-drug conjugate targeting…
All articles by Srivani Venna
Srivani Venna
-
-
BioNTech and DualityBio report positive data for trastuzumab pamirtecan
BioNTech and DualityBio reported encouraging data from a Phase II cohort of their global clinical study evaluating the efficacy of…
-
Sirius and CRISPR dose first subject in trial of thromboembolic disorders therapy
Sirius Therapeutics and CRISPR Therapeutics have dosed the first patient in a Phase II trial of SRSD107 for thromboembolic disorders…
-
WCG unveils clinical trial training solution to cut deviations
WCG has introduced Total Training, a clinical trial solution designed to reduce protocol deviations and enhance site readiness, engagement, and…
-
FDA approves Coya Therapeutics’ trial of COYA 302 for ALS
Coya Therapeutics has announced the acceptance by the US Food and Drug Administration (FDA) of its investigational new drug (IND) application…
-
egnite introduces new research suite to improve patient identification in trials
egnite has launched the CardioCare Research Suite, an advanced component of its flagship platform, aimed at enhancing patient identification processes…
-
FELIQS secures $9m for FLQ-101 to prevent retinopathy of prematurity
FELIQS has concluded a $9m Series A funding round, a significant step towards advancing the FLQ-101 clinical programme for preventing…
-
Javara partners with Cape Fear Valley Health to expand trial access
Javara has formed a strategic collaboration with US-based Cape Fear Valley Health to enhance clinical trial access for patients in…
-
Zydus Lifesciences concludes subject enrolment in Phase II ALS trial
Zydus Lifesciences has announced the conclusion of subject enrolment in the Phase II clinical trial of Usnoflast (ZYIL1) to treat…
-
GlycoMimetics reports positive data from Phase Ia trial of GMI-1687
GlycoMimetics has reported positive initial data from a Phase Ia clinical trial of its E-selectin antagonist, GMI-1687, to potentially treat…